Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 225
- Registration Number
- NCT05379595
- Locations
- 🇺🇸
O Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of California, Los Angeles UCLA, Los Angeles, California, United States
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT05365581
- Locations
- 🇰🇷
Site KR82003, Seocho-gu, Seoul, Korea, Republic of
🇰🇷Site KR82005, Seodaemun-gu, Seoul, Korea, Republic of
🇰🇷Site KR82001, Guro-gu, Seoul, Korea, Republic of
Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 77
- Registration Number
- NCT05330429
- Locations
- 🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Virginia Cancer Specialists, PC, Arlington, Virginia, United States
🇺🇸Seattle Cancer Care Alliance (SCCA), Seattle, Washington, United States
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT05329766
- Locations
- 🇰🇷
Asan Medical Center Hospital, Seoul, Korea, Republic of
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- John Neoptolemos
- Target Recruit Count
- 394
- Registration Number
- NCT05314998
- Locations
- 🇩🇪
Universitätsklinikum Augsburg, III. medizinische Klinik, Augsburg, Germany
🇩🇪DIK Deggendorf, Onkologische Ambulanz, Deggendorf, Germany
🇩🇪Universitätsklinikum Frankfurt, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie,, Frankfurt, Germany
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
- Conditions
- Clinical Stage I Gastric Cancer AJCC v8Clinical Stage II Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Gastric AdenocarcinomaClinical Stage IIA Gastric Cancer AJCC v8Clinical Stage IIB Gastric Cancer AJCC v8Pathologic Stage II Gastric Cancer AJCC v8Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2022-03-25
- Target Recruit Count
- 20
- Registration Number
- NCT05296005
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Conditions
- Myelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously TreatedTreatment-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeAcute Lymphoblastic Leukemia With Failed RemissionMyelodysplastic Syndromes, de NovoLymphoblastic Lymphoma, in RelapseAcute Leukemia of Ambiguous Lineage in RelapseLymphoblastic Lymphoma, RefractoryAcute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Andrew E. Place, MD
- Target Recruit Count
- 92
- Registration Number
- NCT05292664
- Locations
- 🇺🇸
University of California San Francisco-Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT05286814
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05253651
- Locations
- 🇺🇸
Palo Verde Cancer Specialists, Glendale, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
- Conditions
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT05239741
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University ( Site 0051), Chongqing, Chongqing, China
🇨🇳Beijing Cancer hospital-Digestive Oncology ( Site 0001), Beijing, Beijing, China
🇨🇳Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 0011), Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.